Skip to main content
Log in

Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The purpose of this work was to compare technetium-99m-diphosphono-propanedicarboxylate (DPD) and iodine- 123-metaiodobenzylguanidine (MIBG) scans in the diagnosis and follow-up of neuroblastoma, and to study the role of histological differentiation in the uptake of MIBG. The uptake of MIBG and of DPD were studied retrospectively in 27 patients with neuroblastoma (primary, residual and recurrent tumours as well as bone and bone marrow metastases). The findings were related to the histological classification of the tumours as neuroblastoma (N1), differentiating neuroblastoma (N2) or ganglioneuroblastoma (N3). Uptake of MIBG by the primary tumour occurred in 17 of 19 patients, either at diagnosis or during follow-up. There were only two false-negatives with MIBG, both of which were N3. Ten patients were studied preoperatively with both MIBG and DPD. The primary tumour showed MIBG uptake in nine of the ten and DPD uptake in eight of them. Thirty-five sites of cortical bone metastasis were shown in eight patients by both MIBG and DPD, 12 sites in seven patients by MIBG only and seven sites in five patients by DPD only. In 14 patients both MIBG and bone scan were negative. Overall, MIBG demonstrated more lesions than DPD. Retrospectively several hot spots seen only with the bone scan are to be considered as false-positive. The highest incidence of false-negative MIBG and bone scans was observed in ganglioneuroblastoma with a predominance of the more mature component (ganglioneuroma).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lumbroso J, Guermazi F, Hartmann O, et al. Sensibilité et spécificité de la scintigraphie à la Métaiodobenzylguanidine dans l'exploration des neuroblastomes, analyse de 115 examens.Cancer 1988; 75: 97–106.

    Google Scholar 

  2. Feine U, Müller-Schauenburg W, Treuner J, Klingenbiel T. Metaiodobenzylguanidine labeled with123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986.Med Pediatr Oncol 1987; 15: 181–187.

    PubMed  Google Scholar 

  3. Hoefnagel CA, Voûte PA, De Kraker J, Markuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine.J Nucl Med 1987; 28: 308–314.

    PubMed  Google Scholar 

  4. Miceli A, Nespoli L, Burgio GR, Aprile C, Carena M, Spaonaro R. The role of131I benzylguanidine in the diagnosis and follow-up of neuroblastoma.Pediatr Hematol Oncol 1986; 3: 37–47.

    PubMed  Google Scholar 

  5. Voûte PA, Hoefnagel CA, De Kraker J.131I-Meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma.Cancer 1988; 75: 107–111.

    Google Scholar 

  6. Bomanji J, Conry BG, Britton KE, Reznek RH. Imaging neural crest tumors with123I-metaiodobenzylguanidine and X-ray computed tomography. A comparative study.Clin Radiol 1988; 39: 502–506.

    PubMed  Google Scholar 

  7. Müller-Gärtner HA, Ertmann R, Helmke K. Meta-iodobenzylguanidine scintigraphy in neuroblastoma — a comparison with conventional X-ray and ultrsound.Pediatr Hematol Oncol 1986; 3: 97–109.

    PubMed  Google Scholar 

  8. Sisson JC, Frager MS, Gross MD, et al. Scintigraphic localisation of pheochromocytoma.N Engl J Med 1981; 305: 12–17.

    PubMed  Google Scholar 

  9. Kimming B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, Zum Winkel K. Szintigraphische Darstellung eines Neuroblastoms.Nucl Compact 1984; 14: 26–29.

    Google Scholar 

  10. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with [131I]Iodobenzylguanidine.Lancet 1984; I: 333–334.

    Google Scholar 

  11. Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine.Eur J Nucl Med 1990; 16: 325–335.

    PubMed  Google Scholar 

  12. Fischer M, Wehinger H, Kraus C, Ritter J, Schröter W. Treatment of neuroblastoma with131I-metaiodobenzylguanidine. Experience of the Münster/Kassel group.Med Pediatr Oncol 1987; 15: 196–198.

    PubMed  Google Scholar 

  13. Guerra P. Possibilita diagnostiche e terapeutiche della MIBG nel neuroblastoma.Ped Med Chir 1990; 12: 663–668.

    Google Scholar 

  14. Shulkin BL, Shapiro B, Hutchinson RJ. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.J Nucl Med 1992; 33: 1735–1740.

    PubMed  Google Scholar 

  15. Jacobs A, Delree M, Desprechins B, et al. Consolidating the role of I-MIBG scintigraphy in childhood neuroblastoma: five years of clinical experience.Pediatr Radiol 1990; 20: 157–159.

    PubMed  Google Scholar 

  16. Sautter-Bihl M-L, Bihl H, Heinze HG. Stellenwert der99mTc-MDP-Skelettszintigraphie beim Neuroblastom.Nucl Med 1991; 30: 7–12.

    Google Scholar 

  17. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireax C, Pritchard J. Skeletal assesment in neuroblastoma — the pitfalls of iodine-123-MIBG scans.J Nucl Med 1990; 31: 129–134.

    PubMed  Google Scholar 

  18. Hall-Craggs MA, Shaw D, Pritchard J, Gordon I. Metastatic neuroblastoma. new abnormalities on bone scintigraphy may not indicate tumor recurrence.Skeletal Radiol 1990; 19: 33–36.

    PubMed  Google Scholar 

  19. Feggi L, Degli Uberti E, Pansini GC, et al. Pitfalls in scintigraphic detection of neuroendocrine tumors.Eur J Nucl Med 1992; 19: 214–218.

    PubMed  Google Scholar 

  20. Schmiegelow K, Siimes MA, Agertoft L, et al. Radio-iodobenzylguanidine scintigraphy of neuroblastoma: conflicting results, when compared with standard investigations.Med Pediatr Oncol 1989; 17: 126–130.

    Google Scholar 

  21. Moyes JSE, Babich JW, Carter R, Meller ST, Agrawal M, McElwain TJ. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology.J Nucl Med 1989; 30: 474–480.

    PubMed  Google Scholar 

  22. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.J Clin Oncol 1988; 6: 1874–1881.

    PubMed  Google Scholar 

  23. David R, Lamki N, Fan S, et al. The many faces of neuroblastoma.Radiographics 1989; 9: 859–882.

    PubMed  Google Scholar 

  24. Haas D, Ablin AR, Miller C, Zoger S, Matthay KK. Complete pathologic maturation and regression of stage IVs neuroblastoma without treatment.Cancer 1988; 62: 818–825.

    PubMed  Google Scholar 

  25. Evans AE, D'Angio GJ, Sather HN, et al. A comparison of four staging systems for localized and regional neuroblastoma: a report from the Children's Cancer Study Group.J Clin Oncol 1990; 8: 678–688.

    PubMed  Google Scholar 

  26. Joshi VV, Cantor AB, Brodeur GM, et al. Correlation between morphologic and other prognostic markers of neuroblastoma.Cancer 1993; 71: 3173–3181.

    PubMed  Google Scholar 

  27. Joshi VV, Cantor AB, Altshuler G, et al. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification.Cancer 1992: 69: 2183–2196.

    PubMed  Google Scholar 

  28. Lastoria S, Maurea S, Caraco C, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography.Eur J Nucl Med 1993; 20: 1161–1167.

    PubMed  Google Scholar 

  29. Clerico A, Jenkner A, Castello MA, Ciofetta G, Lucarelli C, Codini M. Functionally active ganglioneuroma with increased plasma and urinary catecholamines and positive iodine 131-meta-iodobenzylguanidine scintigraphy.Med Pediatr Oncol 1991; 19: 329–333.

    PubMed  Google Scholar 

  30. Paltiel HJ, Gelfand MJ, Elgazzar AH, et al. Neural crest tumors; I-123 MIBG imaging in children.Radiology 1994; 190: 117–121.

    PubMed  Google Scholar 

  31. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG).Nucl Med Commun 1992; 13: 513–521.

    PubMed  Google Scholar 

  32. Osmsnagaoglou K, Lippens M, Benoit Y, Obrie E, Schelstraete K, Simons M. A comparison of iodine-123 meta-iodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma:Eur J Nucl Med 1993; 20: 1154–1160.

    PubMed  Google Scholar 

  33. Corbett Rolliff J, Fairley N, Moyes J, et al. A prospective comparison between magnetic resonance imaging, meta-iodo-benzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma.Eur J Cancer 1991; 27: 1560–1564.

    PubMed  Google Scholar 

  34. Benz-Bohm G, Gross-Fengels W, Wiedemann B, Linden A. Knochenmarkmetastasierung bei Neuroblastom. MRT im Vergleich zur Knochenmarkzytologie und MIBG-Szintigraphie.Fortschr Röntgenstr 1990; 152: 523–527.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hadj-Djilani, N.L., Lebtahi, N.E., Bischof Delaloye, A. et al. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 22, 322–329 (1995). https://doi.org/10.1007/BF00941848

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00941848

Key words

Navigation